PepGen

2 followers


Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.

Industries

Headquarters

Stage

Employees

Links

Org chart

James McArthur
President & CEO

James McArthur

Collapse
Jaya Goyal
EVP, Research & Preclinical Development
Niels Svenstrup
SVP, Chemistry, Manufacturing & Controls
Michelle Mellion
SVP & Head, Clinical Development
Jeffrey Foy
VP, Toxicology
Debra Sawyer
VP, Quality Assurance
Jane Larkindale
VP, Clinical Science
Hayley Parker
VP, Global Regulatory Affairs